Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals

, MT Newswires - 8:08 AM ET 3/24/2025 default

08:08 AM EDT, 03/24/2025 (MT Newswires) -- Mira Pharmaceuticals ( MIRA ) said Monday it has a signed a binding letter of intent to acquire Skny Pharmaceuticals via a stock transaction.

Under the terms of the letter of intent, Skny shareholders will receive shares of Mira common stock at a valuation determined by an independent third party firm, Mira said.

The transaction includes a $5 million capital infusion of cash or assets into Mira upon closing.

SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation, and all related intellectual property assets will be integrated into Mira upon completion of the transaction, the company said.

The two companies will conduct due diligence for 90 days as they work to finalize a definitive agreement. The transaction is subject to regulatory approvals, board approvals, and a final due diligence review, Mira said.

MIRA shares were 4.6% lower in recent premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.